ストックスクリーナーアプリを入手
7.30
6.88%
0.47
前日終値:
$6.83
開ける：
$7.348
24時間の取引高:
950.55K
Relative Volume:
3.47
時価総額：
$570.52M
収益：
$14.02M
当期純損益:
$-84.03M
株価収益率:
-4.966
EPS:
-1.47
ネットキャッシュフロー:
$-125.54M
1週間 パフォーマンス:
+8.96%
1か月 パフォーマンス:
+13.88%
6か月 パフォーマンス:
+67.82%
1年 パフォーマンス:
+24.57%
1日の値動き範囲:
$6.872
$7.7975
1週間の範囲:
$6.72
$7.7975
52週間の値動き範囲:
$3.85
$7.7975
Meiragtx Holdings Plc Stock (MGTX) Company Profile
名前
Meiragtx Holdings Plc
セクター
電話
646-860-7985
住所
450 EAST 29TH STREET, NEW YORK, NY
MGTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MGTX
Meiragtx Holdings Plc
|
7.30 | 570.52M | 14.02M | -84.03M | -125.54M | -1.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Meiragtx Holdings Plc Stock (MGTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-07-31 | 再開されました | Chardan Capital Markets | Buy |
| 2020-10-23 | 開始されました | RBC Capital Mkts | Outperform |
| 2020-09-15 | 再開されました | BofA Securities | Buy |
| 2019-09-03 | 開始されました | Piper Jaffray | Overweight |
| 2019-02-27 | 繰り返されました | Chardan Capital Markets | Buy |
| 2018-07-03 | 開始されました | Barclays | Overweight |
| 2018-07-03 | 開始されました | BofA/Merrill | Buy |
すべてを表示
Meiragtx Holdings Plc (MGTX) 最新ニュース
MeiraGTx stock rises on data from gene therapy trial - Seeking Alpha
Meiragtx’s gene therapy shows ‘exceptional’ data for blind children - BioWorld Online
MGTX stock soars to 52-week high, reaching $7.39 - Investing.com
MeiraGTx To Advance Gene Therapy For LCA4 Retinal Dystrophy With Positive Phase I/II Results - Nasdaq
MeiraGTx Announces The Lancet Publication of Data Demonstrating the Efficacy of rAAV8.hRKp.AIPL1 for the Treatment of Leber Congenital Amaurosis 4 (LCA4) Retinal Dystrophy - The Manila Times
MeiraGTx Announces Positive Results from First-in-Human Study of Gene Therapy for AIPL1-Related Retinal Dystrophy in Young Children - Nasdaq
Revolutionary Gene Therapy Transforms Children's Vision: The Lancet Validates 100% Success Rate - StockTitan
Kadmon Announces Sale of 1.4 Million Shares of MeiraGTx Holdings plc - ACCESS Newswire
Janney Montgomery Scott LLC Purchases New Stake in MeiraGTx Holdings plc (NASDAQ:MGTX) - MarketBeat
Objective long/short (MGTX) Report - Stock Traders Daily
MeiraGTx (NASDAQ:MGTX) Shares Up 8.6%What's Next? - MarketBeat
Strong week for MeiraGTx Holdings (NASDAQ:MGTX) shareholders doesn't alleviate pain of five-year loss - Simply Wall St
MeiraGTx Holdings plc's (NASDAQ:MGTX) top owners are private equity firms with 25% stake, while 21% is held by institutions - Yahoo Finance
MeiraGTx receives rare pediatric disease designation from FDA for its eye disease treatment - MSN
MeiraGTx Holdings plc (NASDAQ:MGTX) Shares Purchased by JPMorgan Chase & Co. - Defense World
MeiraGTx wins RPD designation for Leber candidate - The Pharma Letter
MeiraGTX CFO Richard Giroux sells $150,960 in ordinary shares - MSN
MeiraGTx Holdings plc (NASDAQ:MGTX) CFO Richard Giroux Sells 24,000 Shares - MarketBeat
MeiraGTx: 2 Possible Near-Term BLA Filings Could Ignite Shareholder Value (NASDAQ:MGTX) - Seeking Alpha
MeiraGTx Receives Rare Pediatric Disease Designation from FDA for AAV8-RK-RetGC for the Treatment of Patients with Leber Congenital Amaurosis Due to GUCY2D Mutations - Marketscreener.com
MeiraGTx Receives Rare Pediatric Disease Designation from FDA for AAV8-RK-RetGC for the Treatment of Patients with Leber Congenital Amaurosis due to GUCY2D Mutations - The Manila Times
MeiraGTx Secures Fourth FDA Rare Pediatric Disease Designation for Gene Therapy Treatment - StockTitan
MeiraGTX CFO Richard Giroux sells $150,960 in ordinary shares By Investing.com - Investing.com South Africa
Long Term Trading Analysis for (MGTX) - Stock Traders Daily
Is MeiraGTx Holdings plc (MGTX) Among Billionaire Joseph Edelman’s Long-Term Stock Picks? - Insider Monkey
Billionaire Joseph Edelman’s Top 10 Long-Term Stock Picks - Insider Monkey
MeiraGTx (NASDAQ:MGTX) Trading 8% HigherWhat's Next? - MarketBeat
Barclays PLC Acquires 76,437 Shares of MeiraGTx Holdings plc (NASDAQ:MGTX) - Defense World
MeiraGTx Holdings plc (NASDAQ:MGTX) Shares Acquired by Barclays PLC - MarketBeat
MeiraGTx Holdings plc (NASDAQ:MGTX) Shares Sold by Jane Street Group LLC - Defense World
Contrasting Innate Pharma (OTCMKTS:IPHYF) and MeiraGTx (NASDAQ:MGTX) - Defense World
MeiraGTx Holdings plc (NASDAQ:MGTX) CEO Sells $231,878.33 in Stock - MarketBeat
MeiraGTX president sells shares worth $305,342 By Investing.com - Investing.com Nigeria
Head-To-Head Survey: Tevogen Bio (NASDAQ:TVGN) and MeiraGTx (NASDAQ:MGTX) - Defense World
Geode Capital Management LLC Cuts Position in MeiraGTx Holdings plc (NASDAQ:MGTX) - Defense World
High Growth Tech Stocks in the United States - Simply Wall St
MeiraGTx Holdings plc (NASDAQ:MGTX) Stock Holdings Lifted by Barclays PLC - Defense World
State Street Corp Boosts Stake in MeiraGTx Holdings plc (NASDAQ:MGTX) - Defense World
How the (MGTX) price action is used to our Advantage - Stock Traders Daily
MeiraGTx Holdings plc (MGTX): Is This Gene Therapy Stock a Good Buy Right Now? - Insider Monkey
FDA Expedites Review of Gene Therapy Co.'s Drug - Streetwise Reports
(MGTX) Trading Signals - Stock Traders Daily
MeiraGTx (NASDAQ:MGTX) Shares Up 10.1%Here's Why - MarketBeat
BNP Paribas Financial Markets Raises Stock Holdings in MeiraGTx Holdings plc (NASDAQ:MGTX) - Defense World
MeiraGTx's SWOT analysis: gene therapy firm's stock faces clinical hurdles - Investing.com
Garden State Investment Advisory Services LLC Invests $1.64 Million in MeiraGTx Holdings plc (NASDAQ:MGTX) - MarketBeat
Investors in MeiraGTx Holdings (NASDAQ:MGTX) have unfortunately lost 71% over the last five years - Yahoo Finance
MetLife Investment Management LLC Reduces Position in MeiraGTx Holdings plc (NASDAQ:MGTX) - Defense World
MeiraGTx's SWOT analysis: gene therapy firm's stock faces pivotal year By Investing.com - Investing.com Nigeria
Meiragtx Holdings Plc (MGTX) 財務データ
収益
当期純利益
現金流量
EPS
0.27%
3.05%
大文字化:
|
ボリューム (24 時間):